

ARIC Manuscript Proposal #731

PC Reviewed: 06/20/00

Status: A

Priority: 2

SC Reviewed: 06/20/00

Status: A

Priority: 2

1. a. Full Title:

Predictors of CVD Events among CHD patients

b. Abbreviated Title (Length 26 characters):

CVD Events in CHD Patients

2. Writing Group (list individual with lead responsibility first):

Lead: Aaron R. Folsom

Address: Division of Epidemiology
School of Public Health
University of Minnesota
Suite 300
1300 South 2nd Street
Minneapolis, MN 55454-1015

Phone: 612-626-8862

Fax: 612-624-0315

E-mail: folsom@epi.umn.edu

Writing group members: Woody Chambless, Gerardo Heiss, Javier Nieto

3. Timeline: Begin summer 2000

4. Rationale:

Among 766 ARIC participants with baseline CHD there have been 219 definite MI or fatal CHD events. 57 have had strokes. It would be interesting to see whether carotid IMT, ankle/brachial index, hemostatic factors, albumin, uric acid, and white blood cell count predict secondary events. A few such studies already exist, but ARIC can contribute further.

Other aims of the paper are to (1) describe hazard rates for secondary events and (2) look at the association of traditional risk factors with recurrence.

5. Main Hypothesis/Study Questions:

1. Traditional risk factors predict recurrent CVD.
2. IMT, ankle/arm, fibrinogen, factor VIII, von Willebrand factor, factor VII, WBC, and uric acid are also associated positively and albumin negatively with CVD events.

6. Data (variables, time window, source, inclusions/exclusions):

Restrict: Participants with prevalent CHD

Dependent: Acute CVD events (CHD plus stroke)

Independent: IMT, ankle/arm, fibrinogen, factor VIII, von Willebrand factor, factor VII, WBC, uric acid, albumin

Covariates: Major baseline risk factors, ECG LVH, meds.

Analyses: Primarily only baseline variables will be considered as predictors of time to event, because many of the independent variables of interest were measured only once. IMT was measured multiple times but issues of drift, etc., make me lean toward not using follow-up values. Covariates could be considered for inclusion as repeated measures.

Although the analysis could include all subjects and test interactions by baseline CHD status (yes, no), I find that approach less appealing.

7. a. Will the data be used for non-CVD analysis in this manuscript? ___ Yes X No

b. If Yes, is the author aware that the file ICTDER01 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES_DNA = "CVD Research" would be used? ___ Yes ___ No

(This file ICTDER01 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8. a. Will the DNA data be used in this manuscript? ___ Yes X No

b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER01 must be used to exclude those with value RES_DNA = "No use/storage DNA"? ___ Yes ___ No